Technical Analysis for CGTX - Cognition Therapeutics, Inc.

Grade Last Price % Change Price Change
D 12.08 0.67% 0.08
CGTX closed up 0.84 percent on Monday, October 18, 2021, on 46 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical CGTX trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.67%
Doji - Bullish? Reversal 0.67%
New 52 Week Closing Low Bearish 1.51%
Hot IPO Pullback Bullish Swing Setup 1.51%
New 52 Week Low Weakness 1.51%
Outside Day Range Expansion 1.51%
New 52 Week Closing Low Bearish -0.25%
Hot IPO Pullback Bullish Swing Setup -0.25%
Outside Day Range Expansion -0.25%
Inside Day Range Contraction -0.98%
Older End-of-Day Signals for CGTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 2 minutes ago
60 Minute Opening Range Breakdown about 1 hour ago
Reversed from Up about 2 hours ago
60 Minute Opening Range Breakout about 3 hours ago
Reversed from Down about 4 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cognition Therapeutics, Inc. Description

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Biology Alzheimer's Disease Disorders Parkinson's Disease Psychiatric Diagnosis Dementia Geriatrics Aging Associated Diseases Cognitive Disorders Lewy Body Dementia Dry Age Related Macular Degeneration Early Stage Alzheimer's Disease

Is CGTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.8
52 Week Low 11.9
Average Volume 227,658
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.53
Resistance 3 (R3) 12.55 12.40 12.44
Resistance 2 (R2) 12.40 12.27 12.39 12.41
Resistance 1 (R1) 12.20 12.18 12.30 12.18 12.38
Pivot Point 12.05 12.05 12.10 12.04 12.05
Support 1 (S1) 11.85 11.92 11.95 11.83 11.62
Support 2 (S2) 11.70 11.83 11.69 11.59
Support 3 (S3) 11.50 11.70 11.56
Support 4 (S4) 11.48